Biotechnology and Biological Products

The UK Biotechnology and Biological market is widely recognised as one of the most advanced in the world with almost twice as many products in development compared to any other European country.

Biotechnology and Biological Products are recognised as follows:

• Biotechnology Products are manufactured by using recombinant DNA technology (genetic manipulation of cells) or a monoclonal antibody.
• Biological Products are defined as such because they are difficult to characterise or control as compared to standard pharmaceuticals. They can be grouped into blood products, vaccines, hormones, peptides and tissue derived products.

In 2006, the pharmaceutical and biotechnology sectors combined were the leading investor in R&D in the UK contributing 10.5% to the overall spend of £21 billion.¹

Please refer to our biotechnology services for further information or contact us to discuss your specific regulatory compliance requirements.

1. Source: UK LifeScience Marketing Strategy Implementation Board unveiled - Peter Mansell, Pharmatimes, 07 April 2008